Cornelis M. Van Bergen

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models.

Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models.

Journal: Blood neoplasia

Published: February 17, 2026

CaClust: linking genotype to transcriptional heterogeneity of follicular lymphoma using BCR and exomic variants.

CaClust: linking genotype to transcriptional heterogeneity of follicular lymphoma using BCR and exomic variants.

Journal: Genome biology

Published: April 17, 2024

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.

Journal: Blood

Published: September 13, 2023

Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.

Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.

Journal: The Journal of experimental medicine

Published: May 31, 2023

Acquisition of a glycosylated B-cell receptor drives follicular lymphoma toward a dark zone phenotype.

Acquisition of a glycosylated B-cell receptor drives follicular lymphoma toward a dark zone phenotype.

Journal: Blood advances

Published: May 26, 2023

Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia.

Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia.

Journal: Haematologica

Published: March 01, 2023

Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.

Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.

Journal: Leukemia

Published: November 29, 2022

VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation.

VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation.

Journal: Cancer immunology research

Published: September 23, 2022

Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.

Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.

Journal: International journal of molecular sciences

Published: October 25, 2021

Templated insertions at VD and DJ junctions create unique B-cell receptors in the healthy B-cell repertoire.

Templated insertions at VD and DJ junctions create unique B-cell receptors in the healthy B-cell repertoire.

Journal: European journal of immunology

Published: June 26, 2020

CACTUS: integrating clonal architecture with genomic clustering and transcriptome profiling of single tumor cells.

CACTUS: integrating clonal architecture with genomic clustering and transcriptome profiling of single tumor cells.

Journal: Genome medicine

Published: June 15, 2020

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 13, 2020

Showing 1-12 of 36

Last Updated: 09/26/2026